← The Wire
RAPPNasdaq
Rapport Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 2012593
Develops precision medicines for neurological and psychiatric disorders using its RAP technology platform
$1.84B
Market cap
$40.39
Last close
+0.8%
1D
+5.8%
5D
436K
Volume
Price · last 39 sessions+13.7%
May 4L $34.37 · H $40.39Jun 29
44
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 10, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 23, 2026DEF 14ADEF 14AApr 23, 20268-KReg FD Disclosure · Company UpdateApr 21, 202610-K10-KMar 10, 20268-KResults of OperationsMar 10, 20268-KCompany UpdateJan 7, 2026424B5424B5Jan 7, 20268-KReg FD Disclosure · Company UpdateJan 7, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KMaterial AgreementSep 10, 2025424B5424B5Sep 10, 2025424B5424B5Sep 8, 20258-KCompany UpdateSep 8, 20258-KReg FD Disclosure · Company UpdateSep 8, 202510-Q10-QAug 7, 20258-KResults of Operations · Reg FD DisclosureAug 7, 20258-KShareholder VoteJun 18, 20258-KReg FD Disclosure · Company UpdateJun 2, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 24, 2025DEF 14ADEF 14AApr 24, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KReg FD Disclosure · Company UpdateMar 3, 20258-KReg FD Disclosure · Company UpdateJan 10, 2025SC 13GARCH VENTURE FUND XII, L.P. - RAPPORT THERAPEUTICS, INC. -- SCH 13GNov 14, 2024SC 13GSEC SCHEDULE 13GNov 13, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 2024SC 13GSC 13GJul 10, 2024SC 13GSC 13GJun 21, 2024SC 13GSC 13GJun 20, 2024SC 13DSC 13DJun 14, 20248-KMaterial Agreement · Equity IssuanceJun 10, 2024424B4424B4Jun 7, 2024S-1/AS-1/AJun 3, 2024S-1S-1May 17, 2024
Insider Activity
In the 90 days to Mar 30, 2026: 4 sold $2.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Gault CherylChief Operating Officer | Sell | 7,161 | $28.04 | $201K |
| Mar 30, 2026 | Gault CherylChief Operating Officer | Sell | 2,839 | $28.55 | $81K |
| Mar 25, 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sell | 10,115 | $29.99 | $303K |
| Mar 5, 2026 | Gault CherylChief Operating Officer | Sell | 2,014 | $28.93 | $58K |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 3,552 | $29.05 | $103K |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 2,983 | $29.04 | $87K |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 2,281 | $29.80 | $68K |
| Feb 18, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 2,100 | $29.80 | $63K |
| Feb 17, 2026 | Bredt DavidChief Scientific Officer | Sell | 5,400 | $28.95 | $156K |
| Feb 17, 2026 | Bredt DavidChief Scientific Officer | Sell | 2,200 | $29.59 | $65K |
| Feb 17, 2026 | Bredt DavidChief Scientific Officer | Sell | 900 | $28.02 | $25K |
| Jan 20, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 5,833 | $26.12 | $152K |
| Jan 20, 2026 | Ceesay AbrahamChief Executive Officer | Sell | 5,083 | $26.11 | $133K |
| Jan 15, 2026 | Bredt DavidChief Scientific Officer | Sell | 8,300 | $26.83 | $223K |
| Jan 15, 2026 | Bredt DavidChief Scientific Officer | Sell | 200 | $27.40 | $5K |
| Dec 31, 2025 | Bredt DavidChief Scientific Officer | Sell | 6,567 | $30.05 | $197K |
| Dec 31, 2025 | Yeleswaram KrishnaswamyChief Development Officer | Sell | 2,840 | $30.05 | $85K |
| Dec 17, 2025 | Ceesay AbrahamChief Executive Officer | Sell | 2,792 | $30.04 | $84K |
| Dec 17, 2025 | Ceesay AbrahamChief Executive Officer | Sell | 2,421 | $30.04 | $73K |
| Dec 17, 2025 | Ceesay AbrahamChief Executive Officer | Sell | 2,441 | $28.84 | $70K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance